Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This compound is a synthetic small molecule with the molecular formula C15H13N3O4S2 and a molecular weight of 363.411. It contains a thiazolidine ring system linked to a furan and benzenesulfonamide moiety. There is no evidence that this compound has been approved for clinical use or advanced beyond early experimental research stages. Its mechanism of action, pharmacological activity, and therapeutic indications are not established in the literature or major drug databases[1][2]. The structure suggests it may have been investigated as an experimental chemical probe or scaffold for further medicinal chemistry optimization.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 4-{5-[(1Z)-1-(2-imino-4-oxo-1,3-thiazolidin-5-ylidene)ethyl]-2-furyl}benzenesulfonamide.